Critical Care Medicine
Dr. Kollef is a Professor of Medicine at Washington University School of Medicine, and is Director of the Medical Intensive Care Unit and Respiratory Care Services at Barnes-Jewish Hospital in St. Louis, Missouri. He is a member of the Barnes-Jewish Hospital Critical Care Committee. Dr. Kollef has lectured extensively on numerous critical care topics, including fungal infection, ventilator-associated pneumonia, antibiotic resistance, and optimization of antibiotic therapy. Dr. Kollef has authored more than 350 peer-reviewed manuscripts, letters, case reports, editorials, and invited publications.
Dr. Kollef is the recipient of numerous honors and awards including selection to “Best Doctors in America,” Central Region and Barnes-Jewish Hospital Team Awards for Quality Improvement for programs directed to VAP prevention, bloodstream infection prevention, and the “Surviving Sepsis Initiative”. He is also a member of the American Thoracic Society, Society of Critical Care Medicine, American Association for Respiratory Care, and American Society of Clinical Investigation. He is a member of the CDC/OID/NPC DCID Defining Surveillance Definitions for VAP and the Chair for Global Anti-Infectives Leadership Academy.
Dr. Wunderink is a Professor of Medicine in the Pulmonary and Critical Care Division of Northwestern University’s Feinberg School of Medicine and Medical Director of the MICU, Northwestern Memorial Hospital. Dr. Wunderink has been active in research and education regarding pulmonary infections, especially ventilator-associated pneumonia and community-acquired pneumonia, and sepsis. He is a member of the last two committees of the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), which developed guideline statements on hospital-acquired and healthcare-associated pneumonia. He co-chaired the most recent IDSA/ATS Consensus Guidelines Committee on the management of community-acquired pneumonia. He has a grant from the CDC to study the incidence and etiology of community-acquired pneumonia in hospitalized patients and from the NIAID for ventilator-associated pneumonia treatment.
Dr. Price is Chief of the Division of Infectious Diseases at Denver Health Medical Center and Assistant Professor of Medicine at the University of Colorado Denver. Dr. Price is the primary investigator on an Agency for Healthcare Research and Quality (AHRQ) initiative toward reducing healthcare-associated infections and a co-investigator on a CDC-funded project in biosurveillance. She chairs the Infection Control and Prevention Committee, Antimicrobial Subcommittee, and Emerging Infectious Diseases Committee and directs the musculoskeletal infection clinic at Denver Health. Her specific research and clinical interests include innovative programs in methicillin-resistant Staphylococcus aureus (MRSA) control, hand-hygiene, the use of molecular typing for infection control investigations, and new technologies for the rapid diagnosis of infectious diseases. Other clinical and research interests focus on the treatment of musculoskeletal infections and the treatment of serious infections due to Staphylococcus aureus. In addition to her membership in the Infectious Diseases Society of America and American Society of microbiology, she is active in the Society of Healthcare Epidemiology of America and has served on a number of their professional committees, in addition to the Colorado Health Facility Acquired Infections Advisory Committee for mandatory infection reporting.